Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
20.29
-0.88 (-4.16%)
Jun 27, 2025, 4:00 PM - Market closed
Celldex Therapeutics Employees
Celldex Therapeutics had 186 employees as of December 31, 2024. The number of employees increased by 26 or 16.25% compared to the previous year.
Employees
186
Change (1Y)
26
Growth (1Y)
16.25%
Revenue / Employee
$40,640
Profits / Employee
-$961,565
Market Cap
1.35B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CLDX News
- 14 days ago - Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewsWire
- 16 days ago - Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 - GlobeNewsWire
- 18 days ago - Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewsWire
- 22 days ago - Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - GlobeNewsWire
- 4 months ago - Celldex Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - GlobeNewsWire